Vyloy

Vyloy (zolbetuximab) is an intravenous therapy for certain gastrointestinal cancers. It targets claudin 18.2 proteins in tumor cells. This monoclonal antibody is prescribed for advanced gastric or gastroesophageal junction adenocarcinoma. Always consult a healthcare provider for suitability.

Vyloy is used to treat adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. It is indicated when tumors express claudin 18.2. This therapy is designed for patients whose cancer has not spread beyond initial treatment options. It is prescribed after confirming biomarker status with a diagnostic test.

As an intravenous infusion, Vyloy works by binding to claudin 18.2 proteins on cancer cells. This action helps the immune system recognize and target tumor cells. Patients may experience infusion-related reactions during administration. Common effects include fatigue, nausea, and vomiting.

Vyloy requires administration under medical supervision in a clinical setting. Patients should report any signs of infusion reactions immediately. Regular monitoring for dehydration and electrolyte imbalances is recommended. Healthcare providers will assess liver function before and during treatment.

Vyloy may interact with medications that affect liver enzymes, such as CYP3A4 inhibitors or inducers. Combining it with live vaccines is not advised during treatment. Patients should inform their doctor about all prescription, over-the-counter, and herbal products they use. Alcohol consumption may increase side effects.